Ardelyx announced on April 24, 2025, that three abstracts supporting IBSRELA (tenapanor) and results from the IBS in America 2024 supplemental survey were accepted for poster presentations at the Digestive Disease Week Conference (DDW), held from May 3-6, 2025. IBSRELA is approved for irritable bowel syndrome with constipation (IBS-C) in adults.
One abstract details the safety and tolerability of tenapanor in pediatric patients with IBS-C, based on blinded safety data from a Phase 3 study and its open-label extension. Another abstract presents data from a Phase 1 study showing that tenapanor and its major metabolite were not detected in the breast milk of healthy lactating females.
A third abstract from the IBS in America 2024 survey explores the correlation between patient-reported IBS-C symptom severity and financial burden. These presentations aim to expand the understanding of IBSRELA's clinical profile and the broader patient experience.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.